MCT INHIBITION SYNERGIZES WITH TYROSINE KINASE AND MTOR INHIBITOR TREATMENT IN RENAL CELL CARCINOMA

被引：0
|
作者：
Jambunathan, Bhaghyasree
Dergham, Abdo
Bhattacharjee, Sayani
Wynn, Rebecca
Sindhwani, Puneet
Petros, Firas
Nadiminty, Nagalakshmi
机构：
来源：
JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD43-03
引用
收藏
页码：E702 / E702
页数：1
相关论文
共 50 条
  • [31] Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus: a quantitative summary
    Klatte, Tobias
    Welsh, Sarah J. J.
    Riddick, Antony C. P.
    Karam, Jose A.
    Stewart, Grant D. D.
    BJU INTERNATIONAL, 2023, 131 (05) : 566 - 568
  • [32] Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
    Mário Fontes-Sousa
    Helena Magalhães
    Alicia Oliveira
    Filipa Carneiro
    Filipa Palma dos Reis
    Pedro Silvestre Madeira
    Sara Meireles
    Advances in Therapy, 2022, 39 : 1107 - 1125
  • [33] Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
    Fontes-Sousa, Mario
    Magalhaes, Helena
    Oliveira, Alicia
    Carneiro, Filipa
    dos Reis, Filipa Palma
    Madeira, Pedro Silvestre
    Meireles, Sara
    ADVANCES IN THERAPY, 2022, 39 (03) : 1107 - 1125
  • [34] Novel role of a tyrosine kinase inhibitor by reversion of immune suppression in renal cell carcinoma
    Seliger, B.
    Mueller, A.
    Giersberg, Corinna
    Handke, Diana
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) inhibitors in patients with renal cell carcinoma
    Montgomery, Jim
    Garofalo, David
    Drenning, Jason
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Tyrosine Kinase Inhibitor Sunitinib Targets the Vasculature of Clear Cell Renal Cell Carcinoma: A Histological and Immunocytochemical Study of Treatment Effect
    Huang, J.
    Thomas, A.
    Simmerman, K.
    Sercia, L.
    Magi-Galluzzi, C.
    Campbell, S.
    Rini, B.
    Zhou, M.
    MODERN PATHOLOGY, 2010, 23 : 197A - 197A
  • [37] Tyrosine Kinase Inhibitor Sunitinib Targets the Vasculature of Clear Cell Renal Cell Carcinoma: A Histological and Immunocytochemical Study of Treatment Effect
    Huang, J.
    Thomas, A.
    Simmerman, K.
    Sercia, L.
    Magi-Galluzzi, C.
    Campbell, S.
    Rini, B.
    Zhou, M.
    LABORATORY INVESTIGATION, 2010, 90 : 197A - 197A
  • [38] Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports
    Schoffski, P.
    Bukowski, R.
    Flodgren, P.
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2009, 20 : I25 - I31
  • [39] SEQUENTIAL USE OF MTOR-INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT
    Busch, J.
    Kempkensteffen, C.
    Gruenwald, V
    Weinkauf, L.
    Hinz, S.
    Magheli, A.
    Miller, K.
    Johannsen, M.
    Weikert, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 231 - 231
  • [40] Tyrosine Kinase Inhibitors in Advanced Renal Cell Carcinoma: The Evolving Treatment Paradigm
    Bukowski, Ronald M.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 9 - 10
12345